Behavioral Processes Underlying Reward Processing in Depression

Last updated: December 4, 2007
Sponsor: Affective Neuroscience Laboratory
Overall Status: Completed

Phase

N/A

Condition

Bipolar Disorder

Depression

Depression (Major/severe)

Treatment

N/A

Clinical Study ID

NCT00205933
2003-P-000994
  • Ages 18-64
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this project is to use behavioral techniques to investigate emotional processing in subjects with major depression and healthy comparison subjects.

Eligibility Criteria

Inclusion

Inclusion Criteria: Depressed participants:

  • Right-handed

  • DSM-IV diagnosis of MDD

  • Score of at least 17 on the 21-item HAM-D scale

  • Absence of any psychotropic medications for at least 2 weeks (6 months fordopaminergic drugs (including methylphenidate), 6 weeks for fluoxetine, and 4 weeksfor neuroleptics and benzodiazepines because of longer half-lives.)

  • No current or past history of MDD with psychotic features

  • Absence of any other Axis I or Axis II diagnosis (Including bipolar disorder andcurrent or lifetime history of alcohol or substance abuse or dependence.)Particularly, subjects with a history of alcoholism and substance abuse will beexcluded, since dopaminergic alterations have been reported in these conditions.Exclusion of patients with comorbid Axis I or Axis II diagnoses will be necessary asevidence exists of alteration in dopamine receptor density in detached personality andsocial phobia. The alteration of dopamine in the brain may in turn alter behavior.

  • Absence of significant medical conditions

  • Absence of ECT in the previous 6 months

  • Ability to provide informed consent/authorization Bipolar participants:

  • Both genders and all ethnic origins

  • Age between 18 and 64

  • Right-handed

  • DSM-IV diagnosis of Bipolar Disorder I or II

  • Score of at least 17 on the 21-item Hamilton Depression Rating Scale (HAM-D)

  • Absence of any psychotropic medications for at least 2 weeks (6 months fordopaminergic drugs (including methylphenidate), 6 weeks for fluoxetine, and 4 weeksfor neuroleptics and benzodiazepines because of longer half-lives.)

  • No current or past history of MDD with psychotic features

  • Absence of any other Axis I or Axis II diagnosis (Including current or lifetimehistory of alcohol or substance abuse or dependence.) Particularly, subjects with ahistory of alcoholism and substance abuse will be excluded.

  • Absence of significant medical conditions

  • Absence of ECT in the previous 6 months

  • Ability to provide informed consent/authorization Control Participants:

  • Right-handed

  • Absence of medical, neurological, and psychiatric illness (including alcohol andsubstance abuse), as assessed by the SCID

  • Absence of any medications for at least 2 weeks

  • Informed consent/authorization

Exclusion

Exclusion Criteria:

  • Left-handed/ambidextrous

  • Evidence of neurological illness

  • Current alcohol or substance abuse

  • Serious suicide or homicide risk

Study Design

Total Participants: 78
Study Start date:
April 01, 2004
Estimated Completion Date:
June 30, 2007

Study Description

A promising strategy for parsing the heterogeneity of Major Depressive Disorder is to identify phenotypes characterized by reliable functional abnormalities. Anhedonia, the lack of reactivity to pleasurable stimuli, is considered a trait marker for depression. Using an objective behavioral task this project aims to investigate hedonic capacity in subjects meeting a DSM-IV diagnosis of Major Depressive Disorder.

Connect with a study center

  • The Depression Clinical and Research Program, Massachusetts General Hospital

    Boston, Massachusetts 02114
    United States

    Site Not Available

  • Affective Neuroscience Laboratory, Department of Psychology, Harvard University

    Cambridge, Massachusetts 02138
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.